Cadila Pharma launches generic version of Ocaliva to treat Primary Biliary Cholangitis

For the treatment of PBC, currently Ursodeoxycholic acid (UDCA) is being extensively used. Around 40% of the patients do not respond to UDCA treatment and 5-10% of patients observe severe side effects. Obetocad can be used as a monotherapy or along with UDCA for the treatment of patients who are unresponsive to UDCA therapy.

"There is an unmet need in the treatment of PBC. Ursodeoxycholic Acid is the only approved standard of care but a major chunk of the patients do not respond to the treatment. Obetocad containing Obetocholic Acid is now DCGI approved and shows positive results in patients. This generic drug is launched for the first time in the country, and with Obetocad, we hope to provide an option to all the patients of PBC" shared Mr. Narendra Deode, Vice President, Cadila Pharmaceuticals.

"With the launch of every product, we strengthen our core philosophy of providing quality medicines to all. With Obetocad, we plan to provide a quality solution to the patients of PBC who do not get relief from other standard therapy options. We are constantly working towards finding the next innovative drug for our patients" said Mr. O.P. Singh, President -Sales and Marketing, Cadila Pharmaceuticals Limited.

Obetocad is available in 5 mg and 10 mg tablets in packs of 10 tablets.

It is also USFDA and EMA approved and recently received its DCGI approvals. Obetocad also has the potential to be used in other indications such as NASH, NAFLD, severe acute hepatitis, bile acid diarrhoea, bariatric and gallstone diseases.

Cadila Pharma has also recently launched 4 biosimilar products in the past 2 months under the brand name Bevaro, Ritucad, Cadalimab, and NuPTH for the treatment of cancer and osteoporosis. Cadila plans to launch multiple biosimilar products this year for the Indian Market.

It has recently concluded and cleared USFDA inspection successfully in February 2020.